StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer detection panel that tests blood for multiple discrete cancer. It also offers ColonSentry, a blood-based test to determine an individual’s current risk for having colorectal cancer. The company is based in Richmond Hill, Canada.